Skip to main content
CVKD
NASDAQ Life Sciences

Cadrenal Therapeutics Launches Phase 2a AKI Trial for CAD-1005, Eyes Pharma Partnering to Secure Funding

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.7
Mkt Cap
$10.613M
52W Low
$3.7
52W High
$15.99
52W Position info
0.0% above low
Off High info
77% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

CVKD is trading near its 52-week low of $3.7 (0.0% above the low) on elevated volume (1.8× avg).

Summary

Cadrenal Therapeutics is launching a Phase 2a clinical trial for its lead drug candidate, CAD-1005, for a new indication: Acute Kidney Injury (AKI). This strategic move aims to attract a well-capitalized pharmaceutical partner and secure non-dilutive funding, which is critical given the company's reiterated going concern warning and cash runway only into October 2026. The AKI market is estimated at $1 billion annually, and the trial's data could also help de-risk the pivotal Phase 3 program for CAD-1005 in heparin-induced thrombocytopenia (HIT), which recently advanced. The company plans to discuss this multi-indication strategy at the upcoming BIO International Convention.

At the time of this announcement, CVKD was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $3.70 to $15.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CVKD - Latest Insights

CVKD
Oct 07, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $1.06 info
Change: -$0.040 (-4%) info
Market Cap: $3.782M info
CVKD
Aug 31, 2026, 8:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.06 info
Change: -$0.440 (-29%) info
Market Cap: $3.782M info
CVKD
Aug 31, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $1.06 info
Change: -$0.570 (-35%) info
Market Cap: $3.782M info
CVKD
Aug 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.86
Real-time Price: $1.06 info
Change: -$0.800 (-43%) info
Market Cap: $3.782M info
CVKD
Aug 03, 2026, 5:12 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.96
Real-time Price: $1.06 info
Change: -$0.900 (-46%) info
Market Cap: $3.782M info